{"id":"cycloset","rwe":[],"tags":[],"trials":[],"_chembl":{"chemblId":"CHEMBL493","moleculeType":"Small molecule","molecularWeight":"654.61"},"aliases":["Bromocriptine Mesylate Quick Release","bromocriptine mesylate"],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$5.3612/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$1,957","description":"CYCLOSET 0.8 MG TABLET","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Cycloset","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:56:13.039180+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:56:18.114925+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cycloset","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:56:18.460926+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL493/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:56:19.153629+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"e42ba916-16b9-4d1c-8d09-9d2fbb1b6c20","title":"CYCLOSET (BROMOCRIPTINE MESYLATE) TABLET [AVVISTO THERAPEUTICS LLC]"},"ecosystem":[],"_scrapedAt":"2026-03-28T00:31:30.294Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:56:20.778519+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03525002","phase":"PHASE2","title":"Dopamine Action on Metabolism in Relation to Genotype","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2018-05-03","conditions":"Obesity","enrollment":120},{"nctId":"NCT07124221","phase":"PHASE3","title":"A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets","status":"RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2025-09-12","conditions":"Hyperprolactinemia","enrollment":382},{"nctId":"NCT05180773","phase":"PHASE4","title":"Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy","status":"RECRUITING","sponsor":"Dennis M. McNamara, MD, MS","startDate":"2022-07-27","conditions":"Peripartum Cardiomyopathy, Postpartum","enrollment":250},{"nctId":"NCT03575000","phase":"PHASE4","title":"Bromocriptine for Patients With Schizophrenia and Prediabetes","status":"NOT_YET_RECRUITING","sponsor":"VA Pittsburgh Healthcare System","startDate":"2026-01-01","conditions":"Schizophrenia, PreDiabetes","enrollment":15},{"nctId":"NCT04413344","phase":"PHASE1, PHASE2","title":"Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease","status":"COMPLETED","sponsor":"Kyoto University","startDate":"2020-06-05","conditions":"Familial Alzheimer Disease (FAD), PSEN1 Mutation","enrollment":8},{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":714582},{"nctId":"NCT04128683","phase":"EARLY_PHASE1","title":"Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2020-10-20","conditions":"Anorexia Nervosa","enrollment":31},{"nctId":"NCT06250257","phase":"PHASE3","title":"Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age","status":"RECRUITING","sponsor":"Jimma University","startDate":"2024-10-21","conditions":"Dilated Cardiomyopathy","enrollment":112},{"nctId":"NCT06556186","phase":"NA","title":"Surgical and Pharmacological Efficacy of Knosp Grade 0-2 Prolactinoma","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-10-01","conditions":"Pituitary Tumor","enrollment":600},{"nctId":"NCT00650520","phase":"PHASE1","title":"Fed Study of (Parlodel®) 2.5 mg Bromocriptine Mesylate Tablets","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2007-05","conditions":"Healthy","enrollment":119},{"nctId":"NCT00649168","phase":"PHASE1","title":"Fed Study of (Parlodel®) Bromocriptine Mesylate Capsules 5 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2007-04","conditions":"Healthy","enrollment":120},{"nctId":"NCT04674670","phase":"NA","title":"Psychobiological Mechanisms Underlying Chronic Pain","status":"COMPLETED","sponsor":"susanne becker","startDate":"2021-11-01","conditions":"Fibromyalgia, Pain, Chronic, Chronic Pain, Widespread","enrollment":48},{"nctId":"NCT02590601","phase":"PHASE3","title":"Bromocriptine in the Treatment of Peripartum Cardiomyopathy","status":"WITHDRAWN","sponsor":"Montreal Heart Institute","startDate":"2017-01-01","conditions":"Peripartum Cardiomyopathy","enrollment":""},{"nctId":"NCT05565976","phase":"PHASE2, PHASE3","title":"Dapagliflozin Effect in Cognitive Impairment in Stroke Trial","status":"UNKNOWN","sponsor":"Jaime Daniel Mondragon","startDate":"2020-08-01","conditions":"Stroke, Ischemic, Mild Cognitive Impairment, Dementia, Vascular","enrollment":270},{"nctId":"NCT05405244","phase":"PHASE3","title":"Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2017-09-19","conditions":"Overweight and Obesity, Eating Behavior","enrollment":55},{"nctId":"NCT02682901","phase":"PHASE4","title":"Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Eastern Virginia Medical School","startDate":"2015-10-05","conditions":"Diabetic Autonomic Neuropathy","enrollment":84},{"nctId":"NCT02929485","phase":"PHASE4","title":"Dopaminergic Modulation of Frontostriatal Function With a Dopamine Agonist and COMT Inhibitor","status":"WITHDRAWN","sponsor":"University of California, Berkeley","startDate":"2013-07","conditions":"Addiction","enrollment":""},{"nctId":"NCT02544321","phase":"PHASE2","title":"Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2015-09","conditions":"Type 1 Diabetes","enrollment":108},{"nctId":"NCT03496545","phase":"PHASE1, PHASE2","title":"Efficacy of Bromocriptine For Fever Reduction in Acute Neurologic Injury","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2018-11-30","conditions":"Subarachnoid Hemorrhage, Subdural Hematoma, Traumatic Brain Injury","enrollment":47},{"nctId":"NCT00990353","phase":"","title":"A Model to Identify Specific Predictors of Spatial Neglect Recovery","status":"UNKNOWN","sponsor":"Kessler Foundation","startDate":"2009-01","conditions":"Spatial Neglect, Hemispatial Neglect, Hemineglect","enrollment":80},{"nctId":"NCT00998556","phase":"PHASE2","title":"Effect of Bromocriptine on Left Ventricular Function in Women With Peripartum Cardiomyopathy","status":"COMPLETED","sponsor":"Hannover Medical School","startDate":"2010-06","conditions":"Peripartum Cardiomyopathy","enrollment":64},{"nctId":"NCT04107480","phase":"PHASE4","title":"PRolaCT - Three Prolactinoma RCTs","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2019-06-21","conditions":"Prolactinoma, Prolactin-Producing Pituitary Tumor","enrollment":880},{"nctId":"NCT04351126","phase":"PHASE2","title":"Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response","status":"COMPLETED","sponsor":"Ganin Fertility Center","startDate":"2019-04-01","conditions":"Ovarian Hyperstimulation Syndrome","enrollment":107},{"nctId":"NCT04181385","phase":"PHASE2, PHASE3","title":"Acute Olanzapine and Lipid Response","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2019-01-01","conditions":"Healthy","enrollment":15},{"nctId":"NCT01474018","phase":"PHASE4","title":"QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2011-11","conditions":"Diabetes Mellitus, Type 2","enrollment":15},{"nctId":"NCT04038749","phase":"NA","title":"Satisfaction of Patients With the Chosen Method of Inhibition of Lactation","status":"UNKNOWN","sponsor":"Żelazna Medical Centre, LLC","startDate":"2019-06-16","conditions":"Lactation Suppressed","enrollment":90},{"nctId":"NCT02299050","phase":"PHASE4","title":"Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2014-06","conditions":"Type 2 Diabetes","enrollment":23},{"nctId":"NCT03384524","phase":"PHASE1, PHASE2","title":"Evaluation of Bromocriptine, Metoprolol and Tamsulosin in Eyes With Non-Central DME","status":"WITHDRAWN","sponsor":"Andrew Moshfeghi, MD, MBA","startDate":"2018-03","conditions":"Diabetic Macular Edema","enrollment":""},{"nctId":"NCT03714763","phase":"NA","title":"Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA)","status":"UNKNOWN","sponsor":"Zhebao Wu","startDate":"2018-11-01","conditions":"Pituitary Adenoma","enrollment":50},{"nctId":"NCT01821001","phase":"PHASE1","title":"Vaginal Bromocriptine for Treatment of Adenomyosis","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2013-03","conditions":"Adenomyosis","enrollment":1},{"nctId":"NCT03353025","phase":"NA","title":"Study on Therapy of Non-invasive Prolactinoma","status":"UNKNOWN","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2016-01-01","conditions":"Prolactinoma","enrollment":394},{"nctId":"NCT01673724","phase":"PHASE4","title":"Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease","status":"COMPLETED","sponsor":"Sandoz","startDate":"2012-02","conditions":"Parkinson's Disease","enrollment":121},{"nctId":"NCT02265484","phase":"NA","title":"To Study the Efficacy of Bromocriptine in Patients With Hepatic/Cirrhosis Related Parkinsonism","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2013-11","conditions":"Cirrhosis Related Parkinsonism","enrollment":50},{"nctId":"NCT02696512","phase":"PHASE1, PHASE2","title":"A Study of IBRF Disorders of Consciousness Advanced Care/MultiModal Care Protocol in Severe Disorders of Consciousness","status":"UNKNOWN","sponsor":"International Brain Research Foundation","startDate":"2016-03","conditions":"Brain Injury","enrollment":30},{"nctId":"NCT02078440","phase":"PHASE1","title":"Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects","status":"COMPLETED","sponsor":"VeroScience","startDate":"2014-01","conditions":"Type 2 Diabetes","enrollment":18},{"nctId":"NCT02846493","phase":"PHASE2","title":"Efficacy and Safety of Dexamethasone Prevention for Patients of Ovarian Hyperstimulation Syndrome","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-08","conditions":"Ovarian Hyperstimulation Syndrome","enrollment":200},{"nctId":"NCT00377676","phase":"PHASE3","title":"Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"VeroScience","startDate":"2004-07","conditions":"Type 2 Diabetes Mellitus","enrollment":3095},{"nctId":"NCT02428946","phase":"NA","title":"Bromocriptine and Insulin Sensitivity","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2014-10","conditions":"Insulin Sensitivity","enrollment":15},{"nctId":"NCT00441363","phase":"PHASE3","title":"Efficacy and Safety of Cycloset® Compared With Placebo When Added to Metformin","status":"TERMINATED","sponsor":"VeroScience","startDate":"2005-02","conditions":"Type 2 Diabetes","enrollment":66},{"nctId":"NCT02428933","phase":"NA","title":"Dopaminergic Effects on Brown Adipose Tissue","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2013-10","conditions":"Obesity","enrollment":8},{"nctId":"NCT02233023","phase":"PHASE4","title":"Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-06","conditions":"Parkinson Disease","enrollment":705},{"nctId":"NCT02172573","phase":"PHASE3","title":"Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1999-04","conditions":"Parkinson Disease","enrollment":315},{"nctId":"NCT02133755","phase":"PHASE3","title":"Effect of Bromocriptine on Insulin Resistance in Polycystic Ovarian Syndrome - A Pilot Study","status":"UNKNOWN","sponsor":"IWK Health Centre","startDate":"2014-07","conditions":"PCOS, Insulin Resistance","enrollment":60},{"nctId":"NCT00240409","phase":"PHASE3","title":"Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-07","conditions":"Parkinson Disease","enrollment":208},{"nctId":"NCT00605683","phase":"PHASE3","title":"MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2007-11","conditions":"Idiopathic Parkinson's Disease","enrollment":679},{"nctId":"NCT01893450","phase":"NA","title":"Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment","status":"TERMINATED","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2008-06","conditions":"Graves Ophthalmopathy","enrollment":31},{"nctId":"NCT00704860","phase":"PHASE4","title":"Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism","status":"COMPLETED","sponsor":"University of Ottawa","startDate":"2005-02","conditions":"Major Depression","enrollment":27},{"nctId":"NCT00004300","phase":"PHASE2","title":"Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis","status":"SUSPENDED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"","conditions":"Stereotyped Behavior, Mental Retardation","enrollment":40},{"nctId":"NCT00451672","phase":"PHASE4","title":"The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2007-01","conditions":"Hyperaldosteronism, Hypertension","enrollment":25},{"nctId":"NCT00315081","phase":"PHASE3","title":"Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine","status":"UNKNOWN","sponsor":"University Hospital, Bonn","startDate":"2006-05","conditions":"Schizophrenia, Hyperprolactinemia","enrollment":20},{"nctId":"NCT00004793","phase":"","title":"Pilot Study of the Effect of Baclofen and Bromocriptine on Luteinizing Hormone Secretion in Pubertal Children","status":"COMPLETED","sponsor":"National Center for Research Resources (NCRR)","startDate":"1995-06","conditions":"Growth Disorders","enrollment":4}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"chemblId":"CHEMBL493"},"formularyStatus":[],"_approvalHistory":[{"date":"20160202","type":"SUPPL","sponsor":"VEROSCIENCE","applicationNumber":"NDA020866"},{"date":"20170206","type":"SUPPL","sponsor":"VEROSCIENCE","applicationNumber":"NDA020866"},{"date":"20130314","type":"SUPPL","sponsor":"VEROSCIENCE","applicationNumber":"NDA020866"},{"date":"20130612","type":"SUPPL","sponsor":"VEROSCIENCE","applicationNumber":"NDA020866"},{"date":"20090505","type":"ORIG","sponsor":"VEROSCIENCE","applicationNumber":"NDA020866"},{"date":"20200817","type":"SUPPL","sponsor":"VEROSCIENCE","applicationNumber":"NDA020866"},{"date":"20151020","type":"SUPPL","sponsor":"VEROSCIENCE","applicationNumber":"NDA020866"},{"date":"20170206","type":"SUPPL","sponsor":"VEROSCIENCE","applicationNumber":"NDA020866"},{"date":"20110324","type":"SUPPL","sponsor":"VEROSCIENCE","applicationNumber":"NDA020866"},{"date":"20200403","type":"SUPPL","sponsor":"VEROSCIENCE","applicationNumber":"NDA020866"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":18,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Cycloset","genericName":"Cycloset","companyName":"Eastern Virginia Medical School","companyId":"eastern-virginia-medical-school","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:56:20.778519+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}